Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 13/20 | 1.00 |
| ▸ | MMP1 | P03956 | 12/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 3/20 | 1.00 |
| ▸ | MMP2 | P08253 | 7/20 | 0.77 |
| ▸ | MMP3 | P08254 | 5/20 | 0.77 |
| ▸ | MMP9 | P14780 | 3/20 | 0.77 |
| ▸ | MMP7 | P09237 | 3/20 | 0.77 |
| ▸ | MMP8 | P22894 | 3/20 | 0.77 |
| ▸ | MMP13 | P45452 | 2/20 | 0.77 |
| ▸ | MMP14 | P50281 | 2/20 | 0.77 |
| ▸ | MMP12 | P39900 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274326 | 1.00 | FCER2 (1.00) | FCER2MMP1ADAM17MMP2MMP3 | |
| SCHEMBL3498576 | 0.90 | FCER2 (0.81) | FCER2MMP1ADAM17MMP2MMP3 | |
| Batimastat SCHEMBL4333 | 0.87 | MMP1 (1.00) | FCER2MMP1ADAM17MMP2MMP3 | |
| Batimastat SCHEMBL20793035 | 0.87 | MMP1 (1.00) | FCER2MMP1ADAM17MMP2MMP3 | |
| Batimastat SCHEMBL22803645 | 0.87 | MMP1 (1.00) | FCER2MMP1ADAM17MMP2MMP3 | |
| Batimastat SCHEMBL17521974 | 0.87 | MMP1 (1.00) | FCER2MMP1ADAM17MMP2MMP3 | |
| Batimastat SCHEMBL12561510 | 0.87 | MMP1 (1.00) | FCER2MMP1ADAM17MMP2MMP3 | |
| Batimastat SCHEMBL10052355 | 0.87 | MMP1 (1.00) | FCER2MMP1ADAM17MMP2MMP3 | |
| Batimastat SCHEMBL12336015 | 0.87 | MMP1 (1.00) | FCER2MMP1ADAM17MMP2MMP3 | |
| Batimastat SCHEMBL4332 | 0.87 | MMP1 (1.00) | FCER2MMP1ADAM17MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | claimed |
| WO-2022107054-A1 | INHIBITORS OF THE ADAM17 ENZYME AND COMPOSITIONS COMPRISING THEM FOR THE EFFECTIVE TREATMENT OF COVID-19 | CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL INSTITUTO POLITÉCNICO NACIONAL (MX) | 2022-05-27 | — | — | WO | disclosed |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-03-13 | — | — | US | disclosed |
| WO-2011011181-A1 | PHARMACOLOGICAL CHAPERONES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | FCER2 1478/4885MMP1 67/4885ADAM17 22/4885 |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | MMP17, MMP25, TIMP3 | FCER2 3711/4885MMP1 16/4885ADAM17 11/4885 |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | PLOD3, MYOC, SLTM | FCER2 1054/4885MMP1 389/4885ADAM17 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.